Aflibercept Biosimilar (Prestige BioPharma)

阿普西柏生物类似药 (Prestige BioPharma)

Report date: 2024/01/30 19:01:19

Base Information

Drug NameAflibercept Biosimilar (Prestige BioPharma)
Drug Alias NamePBP1602PBP-1602
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion proteinBiologics > Biosimilar
Mechanisms of ActionPlacental Growth Factor inhibitorsVascular endothelial growth factor A inhibitors
TargetsPlacental Growth FactorVascular endothelial growth factor A
Therapy Area/IndicationsEye Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySingapore
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesPrestige BioPharma Ltd
China Registration ClassN/A

Develop Information

Active CompaniesPrestige BioPharma Ltd
Inactive CompaniesN/A
Active IndicationsEye Diseases
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A